<DOC>
	<DOCNO>NCT01099670</DOCNO>
	<brief_summary>Healthy subject receive NRL001 placebo daily 14 day . The four treatment group , show , consist 12 subject : Group 1 ; Nine subject receive dose 7.5 mg NRL001 2 g suppository three receive match placebo . Group 2 ; Nine subject receive dose 10 mg NRL001 2 g suppository three receive match placebo . Group 3 ; Nine subject receive daily dose 12.5 mg NRL001 2 g suppository three receive match placebo . Group 4 ; Nine subject receive daily dose 15 mg NRL001 2 g suppository three receive match placebo . The dose group complete prior next group dose . Dose escalation dependent positive assessment safety profile precede group Safety Monitoring Board . The pharmacokinetics NRL001 determine Days 1 , 7 14 . Pharmacodynamics examine use three lead Holter monitor screen interval throughout study period . Adverse event , vital sign , ECGs clinical laboratory parameter collect , tabulate , review record throughout study .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamic Pharmacokinetics 7.5 , 10 , 12.5 15 mg NRL001 2 g Suppository 14 Days</brief_title>
	<detailed_description />
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>Volunteers include study satisfy follow criterion : Healthy adult male female volunteer ( determined medical history , physical examination , laboratory test value , vital sign , exercise stress test electrocardiogram [ ECGs ] screen ) age 1845 year . Nonsmokers three month receive first dose duration study . Body mass index ( BMI ) ≥ 18 ≤ 30 kg/m2 . Able willing receive rectal treatment . Able voluntarily provide write informed consent participate study . Must understand purpose risk study agree follow restriction schedule procedure define protocol . Female volunteer must postmenopausal ( least one year confirm serum FSH screening ) , surgically sterile , practise true sexual abstinence , must use two highly effective method contraception follow throughout study post study physical examination : contraceptive implant , injectables , oral contraceptive , intrauterine device ( IUDs ) , vasectomise partner / barrier method ( condom occlusive cap ) spermicidal foam/gel/film/cream/suppository . Hormonal IUD method contraception must establish period 3 month prior dose change altered study . Females childbearing potential must negative pregnancy test screening ( β HCG ) checkin . Sexually active male volunteer must use condoms partner throughout study 90 day completion study addition partner 's normal mode contraception . Male volunteer must donate sperm study 90 day completion study . Must willing consent data enter The Over Volunteering Prevention System ( TOPS ) . The volunteer 's primary care physician must confirm nothing medical history would preclude enrolment clinical study . Volunteers exclude fulfil follow criterion : Positive HIV , hepatitis B , hepatitis C demonstrate result test screen . History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal ( GI ) , endocrine , immunologic , dermatologic , neurologic psychiatric disease . History presence aortic stenosis hypertrophic cardiomyopathy . History presence clinically significant anorectal condition judge Investigator , clinically significant latex allergy clinically significant drug allergy . Presence ECG abnormality ( rest exercise stress test ) . Pregnant lactating female . Laboratory value screen deem clinically significant accord BioKinetic Europe Ltd SOPs , unless agree advance Sponsor 's Responsible Medical Officer BioKinetic Investigator . Current history drug alcohol abuse positive drug abuse test screening check . Volunteers , opinion Investigator , unsuitable participation study . Participation clinical drug study 90 day precede initial dose study . Any significant illness screen period precede entry study . Donation blood blood product within 90 day prior study drug administration , time study , except require protocol . Strenuous exercise study confinement one week prior dose ( exception screen exercise stress test ) . Consumption alcoholic beverage within 24 hour confinement . Abstinence require study confinement . Consumption xanthinecontaining product within 24 hour confinement study confinement . Use disallow concomitant medication , include overthecounter item within 14 day prior study drug administration end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>